• Antibiotic Clarithromycin Linked To Increased Risk of Cardiac Death
  • September 10, 2014 | Author: Seth A. Katz
  • Law Firm: Burg Simpson Eldredge Hersh & Jardine, P.C. - Englewood Office
  • Danish researchers from the Statens Serum Institut in Copenhagen found the antibiotic clarithromycin increased the risk of cardiac-related deaths.

    Clarithromycin is used to treat numerous bacterial infections including pneumonia, bronchitis and ear, nose, throat and skin infections.

    The researchers observed the health outcomes of more than 5 million adults between the ages of 40 and 74 who received a seven-day course of treatment of either clarithromycin, roxithromycin or penicillin, Medical News Today reported.

    Of the participants, there were 285 cardiac-related deaths, and there was a significant link between the use of clarithromycin and the number of cardiac deaths (76 percent), particularly in women. Compared to penicillin, the risk of a cardiac death when being treated with clarithromycin was 37 deaths per 1 million courses. The use of roxithromycin was associated with 1 cardiac death per 1 million courses compared to penicillin.

    The researchers concluded their study is not reason enough for physicians to change their prescription practices. The increased risk of cardiac death by using clarithromycin is small. However, they believe additional studies are needed to confirm their findings, according to Medical News Today.